The big picture: Walmart will offer over 250 medications, including some GLP-1s for Type 2 diabetes, free to employees starting in 2027.

Why it matters: This move highlights how large self-insured employers are strategically managing rising healthcare costs, particularly for high-demand drugs like GLP-1s, by focusing on chronic disease management.

Between the lines:

• GLP-1s for Type 2 diabetes, insulin, and inhalers will be free with prior authorization.
• The benefit targets diabetes treatment, not broader weight-loss applications of GLP-1s.
• Walmart aims to offset costs through improved adherence and chronic disease control.

Staffing & HR impact: This benefit strategy could enhance talent attraction and retention for Walmart, while other employers may face pressure to re-evaluate their own health benefits to remain competitive. It also underscores the growing complexity of managing employee health plans.

The bottom line: Expect more employers to implement targeted, cost-controlled health benefits to manage expensive drug classes and improve workforce health outcomes.